Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Bailey

Showing results (141-150 of 175) with videos related to

Pageof 18
Sort By:
Acta Neuropathologica|April 4, 2023
Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratificationJack Goddard, Jemma Castle, Emily Southworth, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2010
4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitorsKevin K-C Liu, Shubha Bagrodia, Simon Bailey, et al.
Acta Neuropathologica|April 5, 2016
Risk stratification of childhood medulloblastoma in the molecular era: the current consensusVijay Ramaswamy, Marc Remke, Eric Bouffet, et al.
Neuro-Oncology|October 14, 2022
A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomesKatherine Green, Paraskevi Panagopoulou, Felice D'Arco, et al.
Neuro-Oncology Advances|June 23, 2022
Pediatric high-grade gliomas and the WHO CNS Tumor Classification-Perspectives of pediatric neuro-oncologists and neuropathologists in light of recent updatesGerrit H Gielen, Joshua N Baugh, Dannis G van Vuurden, et al.
Journal of Medicinal Chemistry|November 2, 2011
Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1)Sean T Murphy, Gordon Alton, Simon Bailey, et al.
Ebiomedicine|January 7, 2024
Metabolite profiles of medulloblastoma for rapid and non-invasive detection of molecular disease groupsSarah Kohe, Christopher Bennett, Florence Burté, et al.
The Lancet. Child & Adolescent Health|May 18, 2026
Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort studyStacey Richardson, Debbie Hicks, Melissa Gough, et al.
Eclinicalmedicine|July 1, 2026
Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort studyStacey Richardson, Debbie Hicks, Melissa Gough, et al.
Neuro-Oncology|July 17, 2021
Emergence and maintenance of actionable genetic drivers at medulloblastoma relapseStacey Richardson, Rebecca M Hill, Christopher Kui, et al.
Pageof 18

Showing results (141-150 of 175) with videos related to

Sort By:
Pageof 18
Acta Neuropathologica|April 4, 2023
Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratificationJack Goddard, Jemma Castle, Emily Southworth, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2010
4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitorsKevin K-C Liu, Shubha Bagrodia, Simon Bailey, et al.
Acta Neuropathologica|April 5, 2016
Risk stratification of childhood medulloblastoma in the molecular era: the current consensusVijay Ramaswamy, Marc Remke, Eric Bouffet, et al.
Neuro-Oncology|October 14, 2022
A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomesKatherine Green, Paraskevi Panagopoulou, Felice D'Arco, et al.
Neuro-Oncology Advances|June 23, 2022
Pediatric high-grade gliomas and the WHO CNS Tumor Classification-Perspectives of pediatric neuro-oncologists and neuropathologists in light of recent updatesGerrit H Gielen, Joshua N Baugh, Dannis G van Vuurden, et al.
Journal of Medicinal Chemistry|November 2, 2011
Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1)Sean T Murphy, Gordon Alton, Simon Bailey, et al.
Ebiomedicine|January 7, 2024
Metabolite profiles of medulloblastoma for rapid and non-invasive detection of molecular disease groupsSarah Kohe, Christopher Bennett, Florence Burté, et al.
The Lancet. Child & Adolescent Health|May 18, 2026
Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort studyStacey Richardson, Debbie Hicks, Melissa Gough, et al.
Eclinicalmedicine|July 1, 2026
Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort studyStacey Richardson, Debbie Hicks, Melissa Gough, et al.
Neuro-Oncology|July 17, 2021
Emergence and maintenance of actionable genetic drivers at medulloblastoma relapseStacey Richardson, Rebecca M Hill, Christopher Kui, et al.
Pageof 18